Neurotech International Ltd (NTI) - Net Assets
Based on the latest financial reports, Neurotech International Ltd (NTI) has net assets worth AU$611.14K AUD (≈ $432.42K USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$2.75 Million ≈ $1.94 Million USD) and total liabilities (AU$2.14 Million ≈ $1.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NTI strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$611.14K |
| % of Total Assets | 22.24% |
| Annual Growth Rate | -6.9% |
| 5-Year Change | -57.26% |
| 10-Year Change | -85.77% |
| Growth Volatility | 345.03 |
Neurotech International Ltd - Net Assets Trend (2015–2026)
This chart illustrates how Neurotech International Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see NTI company net worth.
Annual Net Assets for Neurotech International Ltd (2015–2026)
The table below shows the annual net assets of Neurotech International Ltd from 2015 to 2026. Also explore how fast is Neurotech International Ltd growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | AU$611.14K ≈ $432.42K |
-79.32% |
| 2025-06-30 | AU$2.95 Million ≈ $2.09 Million |
-75.17% |
| 2024-06-30 | AU$11.90 Million ≈ $8.42 Million |
+200.32% |
| 2023-06-30 | AU$3.96 Million ≈ $2.80 Million |
+177.06% |
| 2022-06-30 | AU$1.43 Million ≈ $1.01 Million |
-62.97% |
| 2021-06-30 | AU$3.86 Million ≈ $2.73 Million |
+697.48% |
| 2020-06-30 | AU$-646.29K ≈ $-457.29K |
-317.30% |
| 2019-06-30 | AU$297.41K ≈ $210.44K |
-92.97% |
| 2018-06-30 | AU$4.23 Million ≈ $2.99 Million |
-1.49% |
| 2017-06-30 | AU$4.30 Million ≈ $3.04 Million |
-70.34% |
| 2016-06-30 | AU$14.48 Million ≈ $10.25 Million |
+1018.47% |
| 2015-12-31 | AU$1.29 Million ≈ $916.07K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Neurotech International Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5751928800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$52.49 Million | 8589.51% |
| Other Comprehensive Income | AU$6.81 Million | 1114.60% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$611.14K | 100.00% |
Neurotech International Ltd Competitors by Market Cap
The table below lists competitors of Neurotech International Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Arandu Investimentos S.A.
SA:ARND3
|
$16.02 Million |
|
Kwang Jin Ind. Co. Ltd
KQ:026910
|
$16.04 Million |
|
Enero Group Ltd
AU:EGG
|
$16.05 Million |
|
Zenta Group Company Limited Ordinary Shares
NASDAQ:ZGM
|
$16.05 Million |
|
Kresna Graha Investama Tbk PT
JK:KREN
|
$16.00 Million |
|
Indian Terrain Fashions Limited
NSE:INDTERRAIN
|
$16.00 Million |
|
Moatech Co. Ltd
KQ:033200
|
$16.00 Million |
|
Citius Pharmaceuticals Inc
NASDAQ:CTXR
|
$15.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neurotech International Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 2,954,549 to 611,141, a change of -2,343,408 (-79.3%).
- Net loss of 6,538,516 reduced equity.
- Other comprehensive income increased equity by 615,446.
- Other factors increased equity by 3,579,662.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-6.54 Million | -1069.89% |
| Other Comprehensive Income | AU$615.45K | +100.7% |
| Other Changes | AU$3.58 Million | +585.73% |
| Total Change | AU$- | -79.32% |
Book Value vs Market Value Analysis
This analysis compares Neurotech International Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 27.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.12x to 27.08x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-06-30 | AU$0.11 | AU$0.01 | x |
| 2017-06-30 | AU$0.06 | AU$0.01 | x |
| 2018-06-30 | AU$0.04 | AU$0.01 | x |
| 2019-06-30 | AU$0.00 | AU$0.01 | x |
| 2020-06-30 | AU$0.00 | AU$0.01 | x |
| 2021-06-30 | AU$0.01 | AU$0.01 | x |
| 2022-06-30 | AU$0.00 | AU$0.01 | x |
| 2023-06-30 | AU$0.00 | AU$0.01 | x |
| 2024-06-30 | AU$0.01 | AU$0.01 | x |
| 2025-06-30 | AU$0.00 | AU$0.01 | x |
| 2026-06-30 | AU$0.00 | AU$0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neurotech International Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1069.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 4.50x
- Recent ROE (-1069.89%) is below the historical average (-332.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -64.84% | -390.01% | 0.07x | 2.54x | AU$-968.88K |
| 2016 | -28.95% | -1722.11% | 0.01x | 2.04x | AU$-2.93 Million |
| 2017 | -93.87% | -4565.50% | 0.02x | 1.15x | AU$-4.46 Million |
| 2018 | -94.31% | -13280.17% | 0.01x | 1.09x | AU$-4.41 Million |
| 2019 | -1614.66% | -2468.29% | 0.30x | 2.19x | AU$-4.83 Million |
| 2020 | 0.00% | -2214.72% | 0.96x | 0.00x | AU$-1.65 Million |
| 2021 | -192.43% | -3604.58% | 0.04x | 1.30x | AU$-7.82 Million |
| 2022 | -235.12% | -8787.42% | 0.02x | 1.41x | AU$-3.51 Million |
| 2023 | -196.67% | -130759.17% | 0.00x | 1.34x | AU$-8.19 Million |
| 2024 | -42.60% | -258239.99% | 0.00x | 1.03x | AU$-6.26 Million |
| 2025 | -358.73% | -433.60% | 0.75x | 1.10x | AU$-10.89 Million |
| 2026 | -1069.89% | 0.00% | 0.00x | 4.50x | AU$-6.60 Million |
Industry Comparison
This section compares Neurotech International Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $15,249,806
- Average return on equity (ROE) among peers: -47.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neurotech International Ltd (NTI) | AU$611.14K | -64.84% | 3.50x | $16.01 Million |
| Adalta Ltd (1AD) | $7.49 Million | -79.00% | 0.24x | $6.31 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $14.35 Million | 39.55% | 0.08x | $14.31 Million |
| ACRUX Ltd (ACR) | $8.70 Million | -8.79% | 0.64x | $2.61 Million |
| Actinogen Medical Ltd (ACW) | $24.00K | 0.00% | 1.21x | $130.32 Million |
| Argenica Therapeutics Ltd (AGN) | $7.67 Million | -62.81% | 0.24x | $13.18 Million |
| Arovella Therapeutics Ltd (ALA) | $8.84 Million | -33.96% | 0.88x | $48.75 Million |
| Anatara Lifesciences Ltd (ANR) | $924.54K | -218.83% | 0.54x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $30.47 Million | -50.24% | 0.10x | $108.75 Million |
| Amplia Therapeutics Ltd (ATX) | $11.42 Million | -39.44% | 0.30x | $45.40 Million |
| Avecho Biotechnology Ltd (AVE) | $62.61 Million | -17.66% | 0.02x | $60.14 Million |
About Neurotech International Ltd
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute… Read more